Results

Sellas Life Sciences Group Inc.

07/07/2022 | Press release | Distributed by Public on 07/07/2022 05:35

SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009